CD303 is another specific surface marker of human pDCs, centrally involved in antigen presentation and immune tolerance. Monoclonal antibodies directed against CD303 have been studied in preclinical models and have achieved disease control in …

BDCA-2靶点全名为血液树突状细胞抗原2也叫CLEC4C或CD303，是在浆细胞样树突状细胞（PDC）上的唯一表达，是一种II型c型凝集素。 BDCA-2结构. 与BCR信号转导类似，BDCA-2可能是通过与其网格蛋白介导的内吞作用的内化有关，BDCA-2信号传导诱导酪氨酸磷酸化和酪氨酸激酶依赖性钙内流，交联BDCA-2导致受刺激的PDC中 I 型干扰素（IFN-I）产生受到抑制，而PDC是主要的IFN-I生成者。 另外BDCA-2信号传导导致IFN-I基因和IFN-I反应基因的转录水平降低， …

cd303. clec4c、bcda-2. 浆细胞样树突细胞和源自单核细胞的未成熟树突细胞。 捕获抗原并将肽送入用于呈递给 t 细胞的细胞室，可能介导浆细胞样树突细胞中 ifn-α/β 表达诱导的抑制。同时可用作激活蛋白酪氨酸激酶的信号受体，并可使细胞内钙离子流通。 cd304

Jul 11, 2013 · BDCA-2 is a type II C-type lectin receptor selectively expressed on PDCs, where it is involved in antigen capture and in regulation of the production of interferon type I. Dzionek et al 4 originally described the specific reactivity with normal PDCs of the anti-BDCA-2 mouse clone AC144 applied on frozen tissue sections; subsequently, Jaye et al,...

2 days ago · Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens. These molecular markers play a crucial role in diagnosing diseases and developing targeted therapies. Traditional treatment options for BPDCN have demonstrated limited effectiveness, highlighting the need for new and ...

The CD303 (BDCA-2) antigen is a novel type II transmembrane C-type lectin. 3 Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells. 1,3 Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I IFN production, which is ...

CD303 is another specific surface marker of human pDCs, centrally involved in antigen presentation and immune tolerance. Monoclonal antibodies directed against CD303 have been studied in preclinical models and have achieved disease control in …

CD303 (BDCA-2) is a type II c-type lectin specifically expressed by human PDC. CD303 signaling induces tyrosine phosphorylation and Src kinase dependent calcium influx. Cross-linking CD303 results in the inhibition of IFN-I production in stimulated PDC.

We are proposing here, as a new targeted-based therapy, a novel chimeric monoclonal antibody (mAb) that mediates a strong cellular cytotoxicity directed against a specific human pDC marker, CD303. This antibody, ch122A2 mAb, is characterized by low fucose content in its human IgG1 constant (Fc) region, which induces strong in vitro and in vivo ...

CD303 (BDCA-2) is a highly specific marker for normal and neoplastic plasmacytoid dendritic cells and may be useful as a specific marker for the diagnosis of blastic plasmacytoid dendritic cell neoplasm.